Novo's Quiet Comeback Begins

Novo Nordisk ended its dispute with Hims & Hers, enabling Wegovy distribution across a digital platform with ~2.5 million subscribers. The company reported an 82.41% gross margin and 45.50% EBIT margin, with FY25 net profit of DKK 100 billion and operating cash flow approaching DKK 120 billion, supporting major CapEx, acquisitions and shareholder returns. Exceptional profitability materially exceeds sector medians and should underpin upside to sales and shareholder-friendly capital allocation.

Analysis

Direct-to-consumer distribution through a high-engagement digital platform is a structural accelerator for uptake but it shifts the P&L lever from broad marketing to conversion and retention economics; that changes where value is captured (subscription ARPU, margin on recurring dispensing, and upsell services) and creates a natural moat for the digital partner if churn stays below mid-single digits. Third-party competitors without a sticky platform will be forced to match distribution economics (either by building their own, buying one, or increasing rebates), which compresses returns across incumbents and makes manufacturing scale and logistics the primary durable advantage.

Near-term catalysts are flows (prescription conversion, refill rates) and cadence in reported channel mix — these will move sentiment inside 1–3 quarters; medium-term outcomes (12–36 months) hinge on payer behavior, supply chain scale-up and regulatory scrutiny of exclusive channeling. Tail risks that could reverse the move include rapid entrant pricing (new GLP-1-like drugs undercutting realized net price), PBM/formulary countermeasures that blunt DTC pricing power, or manufacturing bottlenecks that force allocation and slow adoption.

A constructive trading stance favors asymmetric optionality into the next 6–18 months while hedging policy/supply shocks: option structures that cap downside but leave ~2–4x upside capture from continued adoption and margin retention are preferred to outright long exposures. Monitor early indicators: weekly prescription data, refill rates at month 1–3, and signs of PBM negotiations or payor pilots — any adverse movement there compresses valuations quickly and is the clearest near-term sell signal.

Contrarian angle: the market is underweight the fragility of realized margins once distribution shifts toward lower acquisition cost but higher service and fulfillment expenses — if fulfillment and patient support costs prove higher than modeled, reported EBIT margins could compress by hundreds of basis points over 12–24 months despite top-line strength. Conversely, investors are also underpricing the optionality for the digital partner to monetize adjacent services (coaching, diagnostics, branded remote care), which would rerate the platform partner multiple materially if they demonstrate >20% incremental margin on ancillary revenues.

Key Decisions for Investors

• NVO — Buy a 12-month call spread (buy ATM call, sell 20% OTM call) sized ~2–3% of risk budget. Rationale: capture continued upside from improved channel monetization and buyback/FCF optionality while capping premium paid; target 2–4x payoff, max loss = premium. Trim on 25–35% realized option gain or if weekly prescriptions slip >15% vs initial run-rate.
• HIMS — Buy 6–9 month OTM calls (~30–40% OTM) or a 6–12 month equity stake sized 1–2% with a 20% stop. Rationale: asymmetric upside from platform monetization and re-rating potential as engagement converts to prescriptions; upside potential 3–5x if conversion stays high, downside limited to premium or 20% drop for equity.
• Pair trade — Long HIMS equity (or calls) vs short LLY (or nearest large GLP-1 pure-play) delta-hedged, 9–18 month horizon. Rationale: isolate rerating of digital distribution premium while hedging macro/therapeutic-cycle risk; target relative outperformance of 20–40% over 12 months, keep net delta near zero and reweight if prescription trends diverge by >20%.
• Hedge/watch — Buy a small, short-dated put on NVO (3 months) or allocate 0.5% notional to protective puts around key policy/earnings windows. Rationale: protect against a sharp de-rating from PBM/payer action or supply allocation headlines; cost is the premium, acceptable to preserve optionality on upside in longer-dated calls.